Celgene BB2121 Multiple Myeloma Retrospective Study

• Research type

  Research Study

• Full title

  A GLOBAL, NON-INTERVENTIONAL,RETROSPECTIVE, MULTI-CENTER STUDY TO GENERATE REAL-WORLD EVIDENCE OF SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH PRIOR EXPOSURE TO AN ANTI-CD38 ANTIBODY.

• IRAS ID

  259625

• Contact name

  Matthew William Jenner

• Contact email

  matthew.jenner@uhs.nhs.uk

• Sponsor organisation

  Celgene

• Duration of Study in the UK

  0 years, 6 months, 31 days

• Research summary

  This is a global non-interventional study with a goal to collect data on relapsed multiple myeloma. The study will look at the subjects who have received at least 3 prior myeloma regimens of treatment (including a proteasome inhibitor(PI), an immunomodulatory agent (IMiD), and an anti-CD38 antibody). The study will also aim to describe demographics, disease characteristics, treatment patterns and clinical outcomes of the study subjects mentioned above.

• REC name

  North East - Newcastle & North Tyneside 1 Research Ethics Committee

• REC reference

  19/NE/0202

• Date of REC Opinion

  13 Jun 2019

• REC opinion

  Favourable Opinion